Results 231 to 240 of about 75,992 (272)

Th17-mediated antitumor immunity in patient-derived organoid and autologous immune cell cocultures predicts response to immunotherapy in head and neck cancer. [PDF]

Immunooncol Technol
Meißner P, Kaps P, Momper T, Wolff A, Raabe I, Strueder DF, Langenkamp U, Brandstetter J, Junghanss C, Becker AS, Zimpfer A, Maletzki C.   +11 more
europepmc   +1 more source

Immunotherapy-Related Cystitis Induced by Nivolumab for Advanced Gastric Cancer: A Case Report. [PDF]

Case Rep Urol
Arinami K, Ito K, Hasegawa G, Takizawa Y, Ikeda Y, Suda T, Hara N, Nishiyama T.   +7 more
europepmc   +1 more source

Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trial. [PDF]

ESMO Gastrointest Oncol
Overman MJ, McCraith S, He B, Jin L, Lei M, Yao J, Morse MA.   +6 more
europepmc   +1 more source

A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer). [PDF]

Future Oncol
Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Matilla Peña A, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M.   +27 more
europepmc   +1 more source

Limited Clinical Benefit of Immune Checkpoint Inhibition in Ovarian Cancer with Opportunities in Selected Subtypes. [PDF]

Int J Mol Sci
Ratka Z, Gamian A, Woźniak M.
europepmc   +1 more source

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Journal of Thoracic Oncology, 2020
INTRODUCTION: Nivolumab monotherapy is approved in the United States for third-line or later metastatic small cell lung cancer based on pooled data from nonrandomized and randomized cohorts of the multicenter, open-label, phase 1/2 trial of nivolumab ...
Matthew D Hellmann, Filippo de Braud, Scott J Antonia   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Nivolumab

Drugs of Today, 2014
Until recently, a treatment for advanced melanoma with a tolerable side effect profile has remained elusive. Therefore, despite its relatively rare occurrence, melanoma continues to cause the majority of skin cancer deaths, with less than 15% of those affected with late-stage disease surviving 10 years or more.
E, Fulchiero, A, Jimeno
openaire   +2 more sources

Nivolumab

Reactions Weekly, 2019
  +9 more sources